Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CC 10004

Known as: CC-10004, CC10004 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
OBJECTIVE To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the… Expand
  • table 1
2012
2012
A broad range of treatments for psoriasis are available, including topical treatments (vitamin D, corticosteroids, calcineurin… Expand
2009
2009
BACKGROUND Thalidomide, one of whose activities is to inhibit Tumour Necrosis Factor (TNF)-α production, has been reported to be… Expand
Review
2007
Review
2007
The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including… Expand
  • table 1
Review
2005
Review
2005
CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential… Expand
2004
2004
Myeloma cells and human umbilical vein endothelial cells (HUVECs) were co‐cultured to model in vitro the interactions between… Expand